Targeting il-17 and th17 cells in rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 36, Issue 2, 2010, Pages 345-366

  Sarkar, Sujata ^a   Fox, David A ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biologic therapeutics; Cytokines; Interleukin 17; Interleukin 23; Interleukin 6; T cell differentiation

Indexed keywords

ADALIMUMAB; CD40 LIGAND; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6 ANTIBODY; LY 2439821; METHOTREXATE; PLACEBO; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CELL TRANSPORT; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; LEUKOPENIA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; TARGET CELL; TH17 CELL; VERTIGO;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; T-LYMPHOCYTES;

EID: 77953256541     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.02.006     Document Type: Review

References (159)

1. Mosmann T.R., Cherwinski H., Bond M.W., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 2005, 175:5.
2. Harrington L.E., Hatton R.D., Mangan P.R., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123.
3. Park H., Li Z., Yang X.O., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133.
4. Yao Z., Painter S.L., Fanslow W.C., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483.
5. Yao Z., Fanslow W.C., Seldin M.F., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3:811.
6. Fossiez F., Djossou O., Chomarat P., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593.
7. Sarkar S., Cooney L.A., White P., et al. Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. Arthritis Res Ther 2009, 11:R158.
8. Murphy K.M., Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2:933.
9. Langrish C.L., Chen Y., Blumenschein W.M., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233.
10. Aggarwal S., Ghilardi N., Xie M.H., et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910.
11. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235.
12. Mangan P.R., Harrington L.E., O'Quinn D.B., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231.
13. Veldhoen M., Hocking R.J., Atkins C.J., et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179.
14. Sutton C., Brereton C., Keogh B., et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006, 203:1685.
15. Nakae S., Iwakura Y., Suto H., et al. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007, 81:1258.
16. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942.
17. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950.
18. Evans H.G., Suddason T., Jackson I., et al. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A 2007, 104:17034.
19. Zhou L., Lopes J.E., Chong M.M., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236.
20. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641.
21. Volpe E., Servant N., Zollinger R., et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9:650.
22. Yang L., Anderson D.E., Baecher-Allan C., et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350.
23. Annunziato F., Cosmi L., Santarlasci V., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849.
24. Amadi-Obi A., Yu C.R., Liu X., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13:711.
25. Hoeve M.A., Savage N.D., de Boer T., et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006, 36:661.
26. Ivanov I.I., McKenzie B.S., Zhou L., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121.
27. Zhang F., Meng G., Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008, 9:1297.
28. Mathur A.N., Chang H.C., Zisoulis D.G., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007, 178:4901.
29. Wei L., Laurence A., Elias K.M., et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007, 282:34605.
30. Fantini M.C., Rizzo A., Fina D., et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007, 37:3155.
31. Zhou L., Ivanov I.I., Spolski R., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967.
32. Korn T., Bettelli E., Gao W., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484.
33. Nurieva R., Yang X.O., Martinez G., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480.
34. Peluso I., Fantini M.C., Fina D., et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007, 178:732.
35. Onoda T., Rahman M., Nara H., et al. Human CD4+ central and effector memory T cells produce IL-21: effect on cytokine-driven proliferation of CD4+ T cell subsets. Int Immunol 2007, 19:1191.
36. Kuestner R.E., Taft D.W., Haran A., et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 2007, 179:5462.
37. Wright J.F., Guo Y., Quazi A., et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 2007, 282:13447.
38. Liang S.C., Long A.J., Bennett F., et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007, 179:7791.
39. Chen Z., Tato C.M., Muul L., et al. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007, 56:2936.
40. Zheng Y., Danilenko D.M., Valdez P., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648.
41. Acosta-Rodriguez E.V., Rivino L., Geginat J., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007, 8:639.
42. Liang S.C., Tan X.Y., Luxenberg D.P., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271.
43. Chung Y., Yang X., Chang S.H., et al. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 2006, 16:902.
44. Boniface K., Bernard F.X., Garcia M., et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174:3695.
45. Wolk K., Witte E., Wallace E., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006, 36:1309.
46. Andoh A., Zhang Z., Inatomi O., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129:969.
47. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647.
48. Anderson C.F., Oukka M., Kuchroo V.J., et al. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007, 204:285.
49. Jankovic D., Kullberg M.C., Feng C.G., et al. Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007, 204:273.
50. McGeachy M.J., Bak-Jensen K.S., Chen Y., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390.
51. Stumhofer J.S., Silver J.S., Laurence A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007, 8:1363.
52. Hirota K., Yoshitomi H., Hashimoto M., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007, 204:2803.
53. Singh S.P., Zhang H.H., Foley J.F., et al. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008, 180:214.
54. Lundy S.K., Lira S.A., Smit J.J., et al. Attenuation of allergen-induced responses in CCR6-/- mice is dependent upon altered pulmonary T lymphocyte activation. J Immunol 2005, 174:2054.
55. Teraki Y., Miyake A., Takebayashi R., et al. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol 2004, 29:658.
56. Varona R., Cadenas V., Flores J., et al. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol 2003, 33:2937.
57. Ruth J.H., Shahrara S., Park C.C., et al. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003, 83:579.
58. Kao C.Y., Huang F., Chen Y., et al. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol 2005, 175:6676.
59. Chabaud M., Page G., Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001, 167:6015.
60. Sato W., Aranami T., Yamamura T. Cutting edge: Human Th17 cells are identified as bearing CCR2+CCR5- phenotype. J Immunol 2007, 178:7525.
61. van der Graaff W.L., Prins A.P., Niers T.M., et al. Quantitation of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology (Oxford) 1999, 38:214.
62. Steiner G., Tohidast-Akrad M., Witzmann G., et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999, 38:202.
63. Isomaki P., Luukkainen R., Lassila O., et al. Synovial fluid T cells from patients with rheumatoid arthritis are refractory to the T helper type 2 differentiation-inducing effects of interleukin-4. Immunology 1999, 96:358.
64. Berner B., Akca D., Jung T., et al. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 2000, 27:1128.
65. Manoury-Schwartz B., Chiocchia G., Bessis N., et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997, 158:5501.
66. Vermeire K., Heremans H., Vandeputte M., et al. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507.
67. Chu C.Q., Song Z., Mayton L., et al. IFNgamma deficient C57BL/6 (H-2b) mice develop collagen induced arthritis with predominant usage of T cell receptor Vbeta6 and Vbeta8 in arthritic joints. Ann Rheum Dis 2003, 62:983.
68. Chu C.Q., Swart D., Alcorn D., et al. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007, 56:1145.
69. Guedez Y.B., Whittington K.B., Clayton J.L., et al. Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain. Arthritis Rheum 2001, 44:2413.
70. Murphy C.A., Langrish C.L., Chen Y., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951.
71. Irmler I.M., Gajda M., Brauer R. Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 2007, 179:6228.
72. Nakae S., Nambu A., Sudo K., et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173.
73. Lubberts E., Koenders M.I., Oppers-Walgreen B., et al. Treatment with a neutralizing antimurine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650.
74. Bush K.A., Farmer K.M., Walker J.S., et al. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002, 46:802.
75. Koenders M.I., Kolls J.K., Oppers-Walgreen B., et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 2005, 52:3239.
76. Lubberts E., Schwarzenberger P., Huang W., et al. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005, 175:3360.
77. Stolina M., Bolon B., Dwyer D., et al. The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers 2008, 13:692.
78. Joosten L.A., Abdollahi-Roodsaz S., Heuvelmans-Jacobs M., et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum 2008, 58:98.
79. Nakae S., Saijo S., Horai R., et al. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 2003, 100:5986.
80. Hirota K., Hashimoto M., Yoshitomi H., et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204:41.
81. Boissier M.C., Chiocchia G., Bessis N., et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995, 25:1184.
82. Finnegan A., Mikecz K., Tao P., et al. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 1999, 163:5383.
83. Hwang S.Y., Kim H.Y. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005, 19:180.
84. Chabaud M., Durand J.M., Buchs N., et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963.
85. Ziolkowska M., Koc A., Luszczykiewicz G., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832.
86. Shahrara S., Huang Q., Mandelin A.M., et al. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008, 10:R93.
87. Raza K., Falciani F., Curnow S.J., et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005, 7:R784.
88. Kim K.W., Cho M.L., Park M.K., et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005, 7:R139.
89. Lenarczyk A., Helsloot J., Farmer K., et al. Antigen-induced IL-17 response in the peripheral blood mononuclear cells (PBMC) of healthy controls. Clin Exp Immunol 2000, 122:41.
90. von Delwig A., Locke J., Robinson J.H., et al. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:143.
91. Kirkham B.W., Lassere M.N., Edmonds J.P., et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006, 54:1122.
92. Lundy S.K., Sarkar S., Tesmer L.A., et al. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 2007, 9:202.
93. Shahrara S., Pickens S.R., Dorfleutner A., et al. IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 2009, 182:3884.
94. Ryu S., Lee J.H., Kim S.I. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006, 25:16.
95. Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett 2004, 93:39.
96. Kotake S., Udagawa N., Takahashi N., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345.
97. Miranda-Carus M.E., Benito-Miguel M., Balsa A., et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006, 54:1151.
98. Sato K., Suematsu A., Okamoto K., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673.
99. Kim K.W., Cho M.L., Kim H.R., et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 2007, 56:1076.
100. Cho M.L., Kang J.W., Moon Y.M., et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006, 176:5652.
101. Caproni M., Antiga E., Melani L., et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009, 29:210.
102. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005, 7:29.
103. Koenders M.I., Lubberts E., van de Loo F.A., et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006, 176:6262.
104. Chabaud M., Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44:1293.
105. Jungel A., Distler J.H., Kurowska-Stolarska M., et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1468.
106. Li J., Shen W., Kong K., et al. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006, 64:515.
107. Young D.A., Hegen M., Ma H.L., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007, 56:1152.
108. Kim H.R., Kim H.S., Park M.K., et al. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 2007, 36:259.
109. Kim H.R., Cho M.L., Kim K.W., et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 2007, 46:57.
110. Lee H.S., Remmers E.F., Le J.M., et al. Association of STAT4 with rheumatoid arthritis in the Korean population. Mol Med 2007, 13:455.
111. Remmers E.F., Plenge R.M., Lee A.T., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977.
112. Hildner K.M., Schirmacher P., Atreya I., et al. Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. J Immunol 2007, 178:3427.
113. Ikeuchi H., Kuroiwa T., Hiramatsu N., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52:1037.
114. Miranda-Carus M.E., Balsa A., Benito-Miguel M., et al. IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate. J Immunol 2004, 173:1463.
115. Yoshihara K., Yamada H., Hori A., et al. IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. Eur J Immunol 2007, 37:2744.
116. Ferrari-Lacraz S., Zanelli E., Neuberg M., et al. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 2004, 173:5818.
117. Yamamura Y., Gupta R., Morita Y., et al. Effector function of resting T cells: activation of synovial fibroblasts. J Immunol 2001, 166:2270.
118. Tran C.N., Lundy S.K., White P.T., et al. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am J Pathol 2007, 171:1588.
119. Stanley K.T., VanDort C., Motyl C., et al. Immunocompetent properties of human osteoblasts: interactions with T lymphocytes. J Bone Miner Res 2006, 21:29.
120. Morita Y., Yang J., Gupta R., et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001, 107:1275.
121. Sarkar S., Tesmer L.A., Hindnavis V., et al. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum 2007, 56:89.
122. Lubberts E., Joosten L.A., Chabaud M., et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697.
123. Kauffman C.L., Aria N., Toichi E., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004, 123:1037.
124. Gottlieb A.B., Cooper K.D., McCormick T.S., et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007, 23:1081.
125. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580.
126. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665.
127. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675.
128. Griffiths C.E., Strober B.E., van de Kerkhof P., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010, 362:118.
129. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633.
130. Sandborn W.J., Feagan B.G., Fedorak R.N., et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130.
131. Segal B.M., Constantinescu C.S., Raychaudhuri A., et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008, 7:796.
132. Reddy M., Davis C., Wong J., et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007, 247:1.
133. Toichi E., Torres G., McCormick T.S., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006, 177:4917.
134. Takagi N., Mihara M., Moriya Y., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998, 41:2117.
135. Atsumi T., Ishihara K., Kamimura D., et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med 2002, 196:979.
136. Guerne P.A., Zuraw B.L., Vaughan J.H., et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989, 83:585.
137. Houssiau F.A., Devogelaer J.P., Van Damme J., et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988, 31:784.
138. Madhok R., Crilly A., Watson J., et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993, 52:232.
139. Firestein G.S., Alvaro-Gracia J.M., Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990, 144:3347.
140. Naka T., Kishimoto T. Joint disease caused by defective gp130-mediated STAT signaling. Arthritis Res 2002, 4:154.
141. Choy E.H., Isenberg D.A., Garrood T., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002, 46:3143.
142. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761.
143. Nishimoto N., Miyasaka N., Yamamoto K., et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009, 68:1580.
144. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817.
145. Smolen J.S., Beaulieu A., Rubbert-Roth A., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987.
146. Genovese M.C., McKay J.D., Nasonov E.L., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008, 58:2968.
147. Emery P., Keystone E., Tony H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516.
148. Jones G., Sebba A., Gu J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88.
149. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162.
150. Nishimoto N., Miyasaka N., Yamamoto K., et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009, 19:12.
151. Nagashima M., Yoshino S., Ishiwata T., et al. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995, 22:1624.
152. Kasama T., Kobayashi K., Yajima N., et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol 2000, 121:533.
153. Koch A.E., Harlow L.A., Haines G.K., et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994, 152:4149.
154. Kremer J., Fleischmann R., Brzezicki J., et al. Tocilizumab inhibits structural joint damage, improves physical function, and increases DAS28 remission rates in RA patients who respond inadequately to methotrexate: the Lithe Study. Ann Rheum Dis 2009, 68:122.
155. Omata Y., Nakamura I., Matsui T., et al. Neutropenia induced by anti-interleukin-6 receptor antibody, tocilizumab. Ann Rheum Dis 2009, 68:582.
156. Genovese M., Van den Bosch F., Roberson S., et al. LY2439821, a Humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 2010, [Epub ahead of print].
157. Durez P., Chindalore V., Bittmer B., et al. AIN457, an anti-IL17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2009, 68:125.
158. Colin E.M., Asmawidjaja P.S., van Hamburg J.P., et al. 1,25-dihydroxyvitamin D(3) modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum 2010, 62:132.
159. Kong J.S., Yoo S.A., Kim H.S., et al. Inhibition of synovial hyperplasia, rheumatoid T cell activation, and experimental arthritis in mice by sulforaphane, a naturally occurring isothiocyanate. Arthritis Rheum 2010, 62:159.